...
search icon
ltrn-img

Lantern Pharma Inc, Common Stock

LTRN

NAQ

$3.69

+$0.09

(2.5%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$39.80M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
91.50K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.57
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.79 L
$11.99 H
$3.69

About Lantern Pharma Inc, Common Stock

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameLTRNSectorS&P500
1-Week Return-5.14%1.07%1.94%
1-Month Return7.58%1.38%-2.02%
3-Month Return8.85%-7.39%1.67%
6-Month Return-23.6%-6.25%6.34%
1-Year Return-1.07%1.24%25.38%
3-Year Return-44.09%6.76%29.66%
5-Year Return-75.32%35.07%78.4%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue1.63K3.39K97.42K154.68K174.84K[{"date":"2019-12-31","value":0.93,"profit":true},{"date":"2020-12-31","value":1.94,"profit":true},{"date":"2021-12-31","value":55.72,"profit":true},{"date":"2022-12-31","value":88.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(1.63K)(3.39K)(97.42K)(154.68K)(174.84K)[{"date":"2019-12-31","value":-162700,"profit":false},{"date":"2020-12-31","value":-338800,"profit":false},{"date":"2021-12-31","value":-9742100,"profit":false},{"date":"2022-12-31","value":-15468100,"profit":false},{"date":"2023-12-31","value":-17484300,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses2.43M5.91M12.59M14.43M17.88M[{"date":"2019-12-31","value":13.58,"profit":true},{"date":"2020-12-31","value":33.05,"profit":true},{"date":"2021-12-31","value":70.43,"profit":true},{"date":"2022-12-31","value":80.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(2.43M)(5.91M)(12.59M)(14.43M)(17.88M)[{"date":"2019-12-31","value":-242818500,"profit":false},{"date":"2020-12-31","value":-590819000,"profit":false},{"date":"2021-12-31","value":-1259150800,"profit":false},{"date":"2022-12-31","value":-1443275300,"profit":false},{"date":"2023-12-31","value":-1787757000,"profit":false}]
Total Non-Operating Income/Expense--296.41K377.16K2.49M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":11.91,"profit":true},{"date":"2022-12-31","value":15.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(2.43M)(5.91M)(12.36M)(14.26M)(15.96M)[{"date":"2019-12-31","value":-242818500,"profit":false},{"date":"2020-12-31","value":-590819000,"profit":false},{"date":"2021-12-31","value":-1236302900,"profit":false},{"date":"2022-12-31","value":-1425994600,"profit":false},{"date":"2023-12-31","value":-1596153400,"profit":false}]
Income Taxes(5.00)(202.91K)(67.93K)(172.81K)(3.00)[{"date":"2019-12-31","value":-500,"profit":false},{"date":"2020-12-31","value":-20290900,"profit":false},{"date":"2021-12-31","value":-6792900,"profit":false},{"date":"2022-12-31","value":-17280700,"profit":false},{"date":"2023-12-31","value":-300,"profit":false}]
Income After Taxes-(5.71M)(12.30M)(14.09M)(15.96M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-570528100,"profit":false},{"date":"2021-12-31","value":-1229510000,"profit":false},{"date":"2022-12-31","value":-1408713900,"profit":false},{"date":"2023-12-31","value":-1596153100,"profit":false}]
Income From Continuous Operations(2.43M)(5.91M)(12.36M)(14.26M)(15.16M)[{"date":"2019-12-31","value":-242818500,"profit":false},{"date":"2020-12-31","value":-590819000,"profit":false},{"date":"2021-12-31","value":-1236302900,"profit":false},{"date":"2022-12-31","value":-1425994600,"profit":false},{"date":"2023-12-31","value":-1515671800,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(2.43M)(5.91M)(12.30M)(14.09M)(15.96M)[{"date":"2019-12-31","value":-242818500,"profit":false},{"date":"2020-12-31","value":-590819000,"profit":false},{"date":"2021-12-31","value":-1229510000,"profit":false},{"date":"2022-12-31","value":-1408713900,"profit":false},{"date":"2023-12-31","value":-1596153400,"profit":false}]
EPS (Diluted)-(1.45)(1.13)(1.31)(1.48)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-145,"profit":false},{"date":"2021-12-31","value":-113,"profit":false},{"date":"2022-12-31","value":-131,"profit":false},{"date":"2023-12-31","value":-148,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

LTRN
Cash Ratio 7.79
Current Ratio 8.31

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

LTRN
ROA (LTM) -28.07%
ROE (LTM) -44.82%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

LTRN
Debt Ratio Lower is generally better. Negative is bad. 0.12
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.88

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

LTRN
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 1.46
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.21

FAQs

What is Lantern Pharma Inc share price today?

Lantern Pharma Inc (LTRN) share price today is $3.69

Can Indians buy Lantern Pharma Inc shares?

Yes, Indians can buy shares of Lantern Pharma Inc (LTRN) on Vested. To buy Lantern Pharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LTRN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Lantern Pharma Inc be purchased?

Yes, you can purchase fractional shares of Lantern Pharma Inc (LTRN) via the Vested app. You can start investing in Lantern Pharma Inc (LTRN) with a minimum investment of $1.

How to invest in Lantern Pharma Inc shares from India?

You can invest in shares of Lantern Pharma Inc (LTRN) via Vested in three simple steps:

  • Click on Sign Up or Invest in LTRN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Lantern Pharma Inc shares
What is Lantern Pharma Inc 52-week high and low stock price?

The 52-week high price of Lantern Pharma Inc (LTRN) is $11.99. The 52-week low price of Lantern Pharma Inc (LTRN) is $2.79.

What is Lantern Pharma Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Lantern Pharma Inc (LTRN) is

What is Lantern Pharma Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Lantern Pharma Inc (LTRN) is 1.46

What is Lantern Pharma Inc dividend yield?

The dividend yield of Lantern Pharma Inc (LTRN) is 0.00%

What is the Market Cap of Lantern Pharma Inc?

The market capitalization of Lantern Pharma Inc (LTRN) is $39.80M

What is Lantern Pharma Inc’s stock symbol?

The stock symbol (or ticker) of Lantern Pharma Inc is LTRN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top